Ezetimibe is a cholesterol absorption inhibitor that reduces the amount of dietary cholesterol taken up by the intestines. It is used to treat high blood cholesterol as an adjunct to diet and other lipid-lowering therapies. The drug works by blocking the npc1l1 transporter on the brush border of enterocytes, preventing cholesterol from entering absorptive cells. This inhibition lowers circulating low-density lipoprotein cholesterol and reduces the risk of atherosclerotic plaque formation. The active metabolite of Ezetimibe modulates intracellular cholesterol trafficking, which leads to increased hepatic ldl receptor expression and enhanced clearance of ldl particles from the bloodstream. Through these actions the medication helps maintain healthier lipid levels without significantly affecting the absorption of other nutrients.

Ezetimibe is a synthetic cholesterol absorption inhibitor used to lower plasma low-density lipoprotein cholesterol concentrations. It acts by blocking the niemann-pick c1-like 1 protein in the intestinal brush border, thereby reducing dietary cholesterol uptake. The inhibition leads to decreased delivery of dietary and biliary cholesterol to the liver, which in turn upregulates the expression of hepatic ldl receptors. Increased ldl receptor activity enhances the clearance of circulating ldl particles from the bloodstream. The downstream reduction in serum cholesterol stimulates the synthesis of bile acids and promotes the conversion of cholesterol into bile salts. By lowering circulating cholesterol, Ezetimibe contributes to a modest regression of atherosclerotic plaque and a decreased risk of cardiovascular events when combined with a statin. Its pharmacological profile is characterized by high specificity for the intestinal cholesterol transporter, minimal systemic absorption, and a long elimination half-life that permits once-daily dosing. Overall the drug achieves its therapeutic effect through targeted blockade of cholesterol uptake, resulting in lower circulating ldl cholesterol and improved cardiovascular outcomes.

The medication may cause mild headache in some users. Dizziness is reported by a noticeable minority. Nausea occasionally appears during the first few days. Fatigue can be experienced after prolonged use. Dry mouth is a frequent complaint among patients. Slight skin rash may develop in sensitive individuals. Insomnia sometimes occurs when taken later in the day. These effects are generally temporary and subside with continued treatment.

The most common side effects include mild headache fatigue and nausea. These reactions are usually temporary and resolve on their own. They often reflect the body's adjustment to new stimuli. Headaches are frequently reported across age groups. Fatigue may be accompanied by a sense of low energy. Nausea tends to be mild and infrequent. Overall these side effects are generally mild and short lived.